Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer

Clinical Cancer Research

Volumn 10, Issue 12 II, 2004, Pages

  Herbst, Roy S ^a   Frankel, Stanley R ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Genta Incorporated   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; DNA; DOCETAXEL; ETOPOSIDE; MESSENGER RNA; OBLIMERSEN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG EFFICACY; FATIGUE; FEVER; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA BINDING; THROMBOCYTOPENIA; TREATMENT OUTCOME;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CATALYSIS; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 3042570458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040018     Document Type: Conference Paper

References (42)

1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
2. Ferreira CG, Epping M, Kruyt FAE, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002;8:2024-34.
3. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature (Lond) 2000;407:810-6.
4. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1:19-30.
5. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
6. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science (Wash DC) 2002;297:1352-4.
7. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (Wash DC) 2001;292:727-30.
8. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
9. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17:2941-53.
10. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000;157:1415-30.
11. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-9.
12. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6:1029-35.
13. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
14. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
15. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 1998;13:397-405.
16. Feinman R, Koury J, Thames M, et al. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999;93:3044-52.
17. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
18. Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 1997;32:9-15.
19. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145:1036-40.
20. Koty PP, Zhang H, Levitt ML. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 1999;23:115-27.
21. Silvestrini R, Costa A, Lequaglie C, et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch 1998;432:441-4.
22. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-7.
23. Krug LM, Miller VA, Filippa DA. Bax, Bcl-2 and drugs affecting tubulin. J Int Assoc Study Lung Cancer 2000;29:S1-40.
24. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science (Wash DC) 1985; 228:1440-3.
25. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42.
26. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-36.
27. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
28. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998;92:712-36.
29. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55.
30. Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001;41:403-19.
31. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
32. Yang D, Ling Y, Almazan M, et al. Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 1999;40:729.
33. van de Donk N, Kamphuis M, van Dijk M, et al. Evaluation of bcl-2 antisense oligonucleotide drugs in multiple myeloma. Blood 2000;96: 757a.
34. van de Donk NW, Kamphuis MM, van Dijk M, et al. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia (Baltimore) 2003;17:211-9.
35. Jansen B, Wacheck V, Heere-Ress E, et al. Clinical, pharmacologic, and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma [abstract]. Proc Am Soc Clin Oncol 2001;1429.
36. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13:539-45.
37. Rudin CM, Kosloff M, Hoffman PC, Edelman MJ, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small cell lung cancer. J Clin Oncol 2004;22:1110-7.
38. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356: 1728-33.
39. de Bono J, Rowinsky E, Kuhn J, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2001;20:474.
40. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8:679-83.
41. Chi KN, Gleave ME, Klasa R, et al. A Phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7:3920-7.
42. Marcucci G, Byrd JC, Dai G, et al. Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003;101: 425-32.